Clinically validated. Naturally derived. Patent-protected.
CannaLean is a clinical-stage biotechnology company developing an innovative CBD-based solution for lowering cholesterol and triglycerides—addressing one of the world’s most widespread metabolic conditions with minimal side effects.
Over 100 million adults worldwide suffer from elevated cholesterol or triglycerides. Existing treatments—primarily statins—are effective for some, but often cause side effects, show limited tolerance, or fail to address triglycerides adequately.
CannaLean is developing a safe, natural, and evidence-based alternative, combining pharmaceutical rigor with wellness accessibility.
Elevated cholesterol
Elevated triglycerides
Pre-clinical studies demonstrated significant reductions in cholesterol and triglyceride levels in animal models, supporting both efficacy and safety.
First-in-human clinical feasibility study (double-blind, placebo-controlled) showed meaningful improvements in lipid profiles, including reductions in LDL-C and total cholesterol.
CannaLean’s formulation has demonstrated strong lipid-lowering efficacy and is adaptable to consumer-friendly wellness formats, including:
Sugar free chocolates, preferably pralines, can be white, milk or dairy free dark.
Sugar free arrange of gelatin based chewable gummies
Either as a powder waiting to be mixed with any drinkable liquid or in a ready drink
These products are designed for daily use, compliance, and accessibility, while remaining grounded in clinical evidence.
Beyond wellness, CannaLean is advancing a pharmaceutical development track, with delivery forms including:
Similar to several antibiotics and drugs marketed today
Either as a powder waiting to be mixed with any drinkable liquid or in a ready drink
As requested in several medical markets
Serial entrepreneur and investor with 40+ years in high-tech and biotech. Founded and led 10+ ventures to successful exits. Combines business vision with hands-on operational leadership. Proven record in building and scaling companies across HealthTech and Hightech.
30+ years of executive experience in finance, investment, and corporate leadership. Former CFO of Channel 13 and partner in a leading hedge fund. Expertise in capital raising, financial strategy, and corporate governance.
Extensive experience in biotech, healthcare, and advanced technologies. Deep knowledge of innovation, formulations, IP management, and regulatory strategy. Proven ability to develop and scale startups from concept to market. B.Sc. in Biology and life science at Tel Aviv University with specialty in biochemistry.
Vast medical experience with an international reputation. Served as Chairman, Department of Medicine and a Hematology Consultant at the Tel Aviv Sourasky (Ichilov) Medical Center. Proficient and experienced with multiple medical and health technologies and fields.
Vast experience as CSO, CTO and other key scientific positions in many biotech companies and startups. Director at Mor Research Applications.
Head of Foot and Ankle Department and Orthopedic Research Unit at HaSharon Hospital. Chairman of the Israeli Cannabis association. Specialist in Medical Cannabis for pain. Serial inventor and Medical Director at various orthopedics companies including Cartiheal.
CannaLean is backed by Clalit Health Services, one of the largest HMOs globally, through its’ TTO Mor, providing:
Access to millions of patients
Community clinics and full-scale hospitals
Lower-cost, efficient clinical trials
Direct collaboration with leading physicians and KOLs
This partnership significantly accelerates validation, scalability, and market readiness.
Under CLALIT are:
Building a clinically validated, IP-protected platform to redefine lipid management across wellness and pharmaceutical markets.
© 2018 All Rights Reserved to CannaLean Biotechs.
